Metastatic Colorectal Cancer - Pipeline Review, H1 2016

  • ID: 3759028
  • Report
  • 718 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Bayer AG
  • EirGenix Inc.
  • Hetero Drugs Limited
  • Merus B.V.
  • Oncolytics Biotech Inc.
  • MORE
Metastatic Colorectal Cancer - Pipeline Review, H1 2016

Summary

‘Metastatic Colorectal Cancer - Pipeline Review, H1 2016’, provides an overview of the Metastatic Colorectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Colorectal Cancer and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer
- The report reviews pipeline therapeutics for Metastatic Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Colorectal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Colorectal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Bayer AG
  • EirGenix Inc.
  • Hetero Drugs Limited
  • Merus B.V.
  • Oncolytics Biotech Inc.
  • MORE
Introduction

Metastatic Colorectal Cancer Overview

Therapeutics Development

Metastatic Colorectal Cancer - Therapeutics under Development by Companies

Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes

Metastatic Colorectal Cancer - Pipeline Products Glance

Metastatic Colorectal Cancer - Products under Development by Companies

Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes

Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development

Metastatic Colorectal Cancer - Therapeutics Assessment

Drug Profiles

Metastatic Colorectal Cancer - Recent Pipeline Updates

Metastatic Colorectal Cancer - Dormant Projects

Metastatic Colorectal Cancer - Discontinued Products

Metastatic Colorectal Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Metastatic Colorectal Cancer, H1 2016

Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Development by Companies, H1 2016 (Contd..7)

Products under Investigation by Universities/Institutes, H1 2016

Metastatic Colorectal Cancer - Pipeline by AB Science SA, H1 2016

Metastatic Colorectal Cancer - Pipeline by AbbVie Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016

Metastatic Colorectal Cancer - Pipeline by Alchemia Limited, H1 2016

Metastatic Colorectal Cancer - Pipeline by Amgen Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Apexigen, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by ArQule, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Array BioPharma Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by AstraZeneca Plc, H1 2016

Metastatic Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H1 2016

Metastatic Colorectal Cancer - Pipeline by Baxalta Incorporated, H1 2016

Metastatic Colorectal Cancer - Pipeline by Bayer AG, H1 2016

Metastatic Colorectal Cancer - Pipeline by Biocon Limited, H1 2016

Metastatic Colorectal Cancer - Pipeline by Bionomics Limited, H1 2016

Metastatic Colorectal Cancer - Pipeline by Bionovis SA, H1 2016

Metastatic Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Metastatic Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016

Metastatic Colorectal Cancer - Pipeline by Celgene Corporation, H1 2016

Metastatic Colorectal Cancer - Pipeline by Celltrion, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Cipla Ltd., H1 2016

Metastatic Colorectal Cancer - Pipeline by Clonz Biotech Private Limited, H1 2016

Metastatic Colorectal Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H1 2016

Metastatic Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016

Metastatic Colorectal Cancer - Pipeline by EirGenix Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Eisai Co., Ltd., H1 2016

Metastatic Colorectal Cancer - Pipeline by Eli Lilly and Company, H1 2016

Metastatic Colorectal Cancer - Pipeline by EnGeneIC Ltd, H1 2016

Metastatic Colorectal Cancer - Pipeline by Etubics Corporation, H1 2016

Metastatic Colorectal Cancer - Pipeline by Exelixis, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Metastatic Colorectal Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016

Metastatic Colorectal Cancer - Pipeline by Gilead Sciences, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Glycotope GmbH, H1 2016

Metastatic Colorectal Cancer - Pipeline by Hemispherx Biopharma, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Hetero Drugs Limited, H1 2016

Metastatic Colorectal Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016

Metastatic Colorectal Cancer - Pipeline by Ignyta, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Immatics Biotechnologies GmbH, H1 2016

Metastatic Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd., H1 2016

Metastatic Colorectal Cancer - Pipeline by Immunomedics, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2016

Metastatic Colorectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Mabion SA, H1 2016

Metastatic Colorectal Cancer - Pipeline by Mabtech Limited, H1 2016

Metastatic Colorectal Cancer - Pipeline by mAbxience S.A., H1 2016

Metastatic Colorectal Cancer - Pipeline by MacroGenics, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by MedImmune, LLC, H1 2016

Metastatic Colorectal Cancer - Pipeline by Merck & Co., Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Merck KGaA, H1 2016

Metastatic Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Merus B.V., H1 2016

Metastatic Colorectal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Mologen AG, H1 2016

Metastatic Colorectal Cancer - Pipeline by Morphotek, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Mycenax Biotech Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Natco Pharma Limited, H1 2016

Metastatic Colorectal Cancer - Pipeline by Nektar Therapeutics, H1 2016

Metastatic Colorectal Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2016

Metastatic Colorectal Cancer - Pipeline by Novartis AG, H1 2016

Metastatic Colorectal Cancer - Pipeline by OBI Pharma, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Oncobiologics, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Panacea Biotec Limited, H1 2016

Metastatic Colorectal Cancer - Pipeline by Pfizer Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Pharma Mar, S.A., H1 2016

Metastatic Colorectal Cancer - Pipeline by Pharmacyclics, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Precision Biologics, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by PsiOxus Therapeutics Limited, H1 2016

Metastatic Colorectal Cancer - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2016

Metastatic Colorectal Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016

Metastatic Colorectal Cancer - Pipeline by Sillajen Biotherapeutics, H1 2016

Metastatic Colorectal Cancer - Pipeline by Symphogen A/S, H1 2016

Metastatic Colorectal Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016

Metastatic Colorectal Cancer - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016

Metastatic Colorectal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2016

Metastatic Colorectal Cancer - Pipeline by Tocagen Inc., H1 2016

Metastatic Colorectal Cancer - Pipeline by Vaximm AG, H1 2016

Metastatic Colorectal Cancer - Pipeline by XBiotech USA, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Metastatic Colorectal Cancer Therapeutics - Recent Pipeline Updates, H1 2016

Metastatic Colorectal Cancer - Dormant Projects, H1 2016

Metastatic Colorectal Cancer - Dormant Projects (Contd..1), H1 2016

Metastatic Colorectal Cancer - Dormant Projects (Contd..2), H1 2016

Metastatic Colorectal Cancer - Dormant Projects (Contd..3), H1 2016

Metastatic Colorectal Cancer - Dormant Projects (Contd..4), H1 2016

Metastatic Colorectal Cancer - Dormant Projects (Contd..5), H1 2016

Metastatic Colorectal Cancer - Dormant Projects (Contd..6), H1 2016

Metastatic Colorectal Cancer - Dormant Projects (Contd..7), H1 2016

Metastatic Colorectal Cancer - Dormant Projects (Contd..8), H1 2016

Metastatic Colorectal Cancer - Discontinued Products, H1 2016

Metastatic Colorectal Cancer - Discontinued Products (Contd..1), H1 2016

Metastatic Colorectal Cancer - Discontinued Products (Contd..2), H1 2016

List of Figures

Number of Products under Development for Metastatic Colorectal Cancer, H1 2016

Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AB Science SA
AbbVie Inc.
Actinium Pharmaceuticals, Inc.
Advenchen Laboratories, LLC
Alchemia Limited
Amgen Inc.
Apexigen, Inc.
ArQule, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Bavarian Nordic A/S
Baxalta Incorporated
Bayer AG
Biocon Limited
Bionomics Limited
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Celltrion, Inc.
Cipla Ltd.
Clonz Biotech Private Limited
Coherus BioSciences, Inc.
Cornerstone Pharmaceuticals, Inc.
DanDrit Biotech A/S
Dr. Reddy's Laboratories Limited
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EnGeneIC Ltd
Etubics Corporation
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Genor BioPharma Co., Ltd.
Gilead Sciences, Inc.
Glycotope GmbH
Hemispherx Biopharma, Inc.
Hetero Drugs Limited
Hutchison MediPharma Limited
Ignyta, Inc.
Immatics Biotechnologies GmbH
Immodulon Therapeutics Ltd.
Immunomedics, Inc.
Immunovative Therapies, Ltd.
Karyopharm Therapeutics, Inc.
Mabion SA
Mabtech Limited
mAbxience S.A.
MacroGenics, Inc.
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Merus B.V.
Millennium Pharmaceuticals, Inc.
Mologen AG
Morphotek, Inc.
Mycenax Biotech Inc.
Natco Pharma Limited
Nektar Therapeutics
Nippon Kayaku Co., Ltd.
Novartis AG
OBI Pharma, Inc.
Oncobiologics, Inc.
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Panacea Biotec Limited
Pfizer Inc.
Pharma Mar, S.A.
Pharmacyclics, Inc.
Precision Biologics, Inc.
PsiOxus Therapeutics Limited
Reliance Life Sciences Pvt. Ltd.
Shanghai Henlius Biotech Co., Ltd.
Sillajen Biotherapeutics
Symphogen A/S
Syndax Pharmaceuticals, Inc.
Taiho Pharmaceutical Co., Ltd.
TaiwanJ Pharmaceuticals Co., Ltd.
TetraLogic Pharmaceuticals
Tocagen Inc.
Vaximm AG
XBiotech USA, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll